Poor Treatment Response in Multiple Sclerosis Linked to Exaggerated Biological Response to IFNβ
Author Information
Author(s): Rudick Richard A., Rani M. R. Sandhya, Xu Yaomin, Lee Jar-Chi, Na Jie, Shrock Jennifer, Josyula Anupama, Fisher Elizabeth, Ransohoff Richard M.
Primary Institution: Cleveland Clinic
Hypothesis
The molecular response to IFNβ correlates with treatment response in individual patients with MS.
Conclusion
Patients with poor treatment response to IFNβ exhibit an exaggerated biological response to the treatment.
Supporting Evidence
- 85 patients were analyzed for their response to IFNβ treatment.
- Patients with poor response had a higher number of new brain lesions.
- An exaggerated molecular response was observed in patients classified as poor responders.
Takeaway
Some people with multiple sclerosis don't get better with a medicine called IFNβ because their bodies react too strongly to it.
Methodology
The study analyzed the molecular response to IFNβ in 85 MS patients using a customized cDNA macroarray assay for 166 IFN-regulated genes.
Potential Biases
Potential bias due to lack of a control group and reliance on MRI for treatment response classification.
Limitations
There was no placebo group, and the study relied solely on MRI outcomes to classify treatment response.
Participant Demographics
Mean age was 35.7 years; 65% were women; 91% were white; 32% had clinically isolated syndrome.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website